Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers
KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers. Oncogenic mutations, primarily at codons 12, 13, and 61, lock KRAS into a GTP-bound active state, thus resulting in constitutive signaling through downstream effectors such as RAF and phosphoinositide
Authors
- Zhengke Lian (ORCID: https://orcid.org/0000-0001-8010-4616)
- Xuanzheng Xiao
- Ao Zhang (ORCID: https://orcid.org/0000-0001-7205-9202)
- Juanjuan Feng
- Xiufeng Pang
Institutions
- Chongqing Normal University (CN)
- Shanghai Innovative Research Center of Traditional Chinese Medicine (CN)
- East China Normal University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2026-02-09
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0612
- Primary Topic
- Protein Kinase Regulation and GTPase Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Centre Scientifique et Technique du Bâtiment